Legislative Proposals to Tackle Improper Pharmaceutical Patents in the Orange Book
Drug Patent Watch
JANUARY 22, 2024
A recent article published in Health Affairs, delves into the Federal Trade Commission’s (FTC) concerns regarding the inclusion of improper patents in the FDA’s Orange Book by pharmaceutical manufacturers.
Let's personalize your content